Our actual results may differ materially from these plans and expectations, and the impact and duration of the COVID-19 pandemic is unknown.
Finally, our remarks today will include references to non-GAAP net income and diluted earnings per share, which are financial measures that are not defined under Generally Accepted Accounting Principles.
So I'd like to take a few minutes to review our current state of operations around the world.
Overall, Bio-Rad has adapted well to the working constraints that COVID has imposed upon us, and we find ourselves able to respond and react well to everyday operational changes and demands.
With improvement in our end markets after the significant downturn a year ago, we're responding well to increased demand.
We also continue to experience higher than typical logistics costs as indicated in our Q1 call.
Now I would like to review the results of the second quarter.
Net sales for the second quarter of 2021 were $715.9 million, which is a 33.4% increase on a reported basis versus $536.9 million in Q2 of 2020.
